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Abstract
Background: Transient stimulation of the innate immune system by an intraperitoneal injection of
lipopolysaccharide (LPS) activates peripheral and central expression of the tryptophan degrading enzyme
indoleamine 2,3 dioxygenase (IDO) which mediates depressive-like behavior. It is unknown whether direct
activation of the brain with LPS is sufficient to activate IDO and induce depressive-like behavior.
Methods: Sickness and depressive-like behavior in C57BL/6J mice were assessed by social exploration and the
forced swim test, respectively. Expression of cytokines and IDO mRNA was measured by real-time RT-PCR and
cytokine protein was measured by enzyme-linked immunosorbent assays (ELISAs). Enzymatic activity of IDO was
estimated as the amount of kynurenine produced from tryptophan as determined by high pressure liquid
chromatography (HPLC) with electrochemical detection.
Results: Intracerebroventricular (i.c.v.) administration of LPS (100 ng) increased steady-state transcripts of TNFa, IL-6
and the inducible isoform of nitric oxide synthase (iNOS) in the hippocampus in the absence of any change in
IFNg mRNA. LPS also increased IDO expression and induced depressive-like behavior, as measured by increased
duration of immobility in the forced swim test. The regulation of IDO expression was investigated using in situ
organotypic hippocampal slice cultures (OHSCs) derived from brains of newborn C57BL/6J mice. In accordance
with the in vivo data, addition of LPS (10 ng/ml) to the medium of OHSCs induced steady-state expression of
mRNA transcripts for IDO that peaked at 6 h and translated into increased IDO enzymatic activity within 8 h post-
LPS. This activation of IDO by direct application of LPS was preceded by synthesis and secretion of TNFa and IL-6
protein and activation of iNOS while IFNg expression was undetectable.
Conclusion: These data establish that activation of the innate immune system in the brain is sufficient to activate
IDO and induce depressive-like behavior in the absence of detectable IFNg. Targeting IDO itself may provide a
novel therapy for inflammation-associated depression.
Background
Clinical and animal studies implicate systemic inflamma-
tion in the pathogenesis of major depressive disorders
by activating immune-to-brain communication pathways
[1-5]. Proinflammatory cytokines induce symptoms of
sickness that correspond to a temporary reorganization
of the organism’s priorities to cope with infections. If
the neuroimmune inflammatory response does not
resolve, sickness behavior can culminate in depressive-
like behavior [2,6]. Inflammation-induced depression is
associated with activation of the tryptophan degrading
enzyme indoleamine 2,3 dioxygenase (IDO) in both the
brain and periphery. IDO is a ubiquitous enzyme that
degrades tryptophan into kynurenine, which can
decrease the bioavailability of tryptophan for the synth-
esis of serotonin [7-11]. The kynurenine/tryptophan
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animals following both acute and chronic stimulation of
the immune system [12-17]. Kynurenine can be further
degraded into a number of neuroactive metabolites that
act as agonists or antagonists of the NMDA receptor
that can ultimately impact on glutamatergic neurotrans-
mission [18-20].
Sickness is an adaptive response to infectious patho-
gens. Although sickness and depression can share symp-
toms, the similarities are only partial. Sickness rather
than depression is fully reversible once the pathogen has
been eliminated [2]. In both mice injected with lipopoly-
saccharide (LPS) or infected with Bacille Calmette-
Guerin, depressive-like behavior remains after sickness
behavior had abated [2]. Systemic administration of LPS
is a well-established model to study behavioral and phy-
siological responses following peripheral activation of
the immune system. Sickness behavior peaks in the first
2 to 6 h following intraperitonal injection of LPS and
gradually returns to normal [2,14,21]. Twenty four
hours after treatment, when sickness behavior has
diminished, depressive-like behavior still remains, as
measured by increased immobility in both the forced
swim test (FST) and tail suspension test and decreased
preference for a sweetened solution [2,14,21]. These
findings indicate that the LPS model of peripheral acute
immune activation can dissociate sickness from
depression.
Activation of IDO is a key event in the switch from
sickness to depression. Blockade of cytokine production
and IDO activation by administration of the anti-inflam-
matory tetracycline derivative minocycline prevents both
LPS-induced sickness behavior and depressive-like beha-
vior [14,22]. Administration of the IDO competitive
inhibitor 1-methyl tryptophan abrogates development of
LPS-induced depressive-like behavior without altering
LPS-induced expression of proinflammatory cytokines
and the development of sickness behavior [14].
In all the experiments carried out to date with sys-
temic administration of LPS, IDO is activated both per-
ipherally and in the brain. Peripherally activated IDO
produces large quantities of kynurenine that can enter
the brain via the same transporter as that for tryptophan
[23,24]. This is important because peripherally adminis-
tered kynurenine can induce depressive-like behavior in
naive mice [14]. Although IDO is predominantly
expressed in peripheral organs such as the lungs, it is
also present in the brain where it can be activated by
immune and non-immune stimuli [2]. However, the
exact brain structures in situ where IDO is activated are
less well known. Classic neurocircuitry of depression
often refers to cortical-striatal-limbic networks of neural
circuits that involve the sub-genual anterior cingulate
cortex [25]. However, it is less appreciated that the
hippocampus is another braina r e at h a tp l a y sar o l ei n
the pathophysiology of major depressive disorders. It
has been extensively studied in patients with mood dis-
orders [26,27] and is an important structure in the neu-
rogenesis theory of depression [26,28]. In mice, the
hippocampus is also related to depressive-like behavior
[21,29]. Indeed, IDO is activated in the mouse [22,29,30]
and rat [31] hippocampus following systemic adminis-
tration of LPS. It is not yet known whether LPS admi-
nistered directly in the cerebral ventricles is able to
activate IDO in the hippocampus concomitantly with its
ability to induce depressive-like behavior. Therefore, one
of the questions we sought to answer is whether activa-
tion of IDO in the brain is sufficient to induce depres-
sive-like behavior.
In order to study the mechanisms involved in the acti-
vation of IDO by central administration of LPS, we used
organotypic hippocampal slice cultures (OHSCs) that
have the advantage of preserving the basal cellular and
connective organization of this brain area and several
fundamental in vivo-like characteristics such as glial-
neuronal interactions [32,33]. This preparation has pre-
viously been used for studying the detrimental effects of
proinflammatory cytokines on long-term potentiation in
the rat system [34,35]. We show for the first time that
centrally administered LPS is sufficient to activate IDO
in the hippocampus and induce depressive-like behavior.
Using organotypic hippocampal slice cultures we further
demonstrate that this brain area responds to LPS by
increased expression of IDO and cytokines, followed by
activation of IDO. Finally, both the in vivo and in situ
data support the idea that IDO can be regulated in an
IFNg-independent manner [36,37]. These new findings
point to the role of brain IDO in inflammation-induced
depression.
Methods
Reagents
LPS was from Escherichia coli 0127:B8 (cat# L-3137).
Heat-inactivated horse serum (cat# SH30074.03), Hank’s
balanced salt solution (HBSS, cat# SH30030.03) and
MEM (cat# SH30024.02) were all from Hyclone. Gey’s
balanced salt solution (GBSS, cat# G9779) was from
Sigma. D-glucose (cat# 15023-021) was from GibcoBRL
and propidium iodide (PI, cat# P3566) was from Mole-
cular Probes Inc. (Eugene, OR). Kits for enzyme-linked
immunosorbent assay (ELISA) were from R&D Systems
(Wiesbaden, DE). TRIzol reagent was from Invitrogen
Life Technologies (Carlsbad, CA). Reagents for RT-PCR
were all from Applied Biosystems as follows: Ambion
(cat# 1710) reverse transcriptase kit, Ambion’sD N A -
free™ DNase treatment and removal reagents (cat#
AM1906), RT-PCR primers for TNFa (cat#
Mm00443258_m1), IL-6 (cat# Mm00446190_m1), IFNg
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the inducible isoform of nitric oxide synthase (iNOS)
(cat# Mm00440485_m1) and glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH; cat# Mm999999_g1).
The protease inhibitor cocktail (cat# P2714) was from
Sigma.
Mice
All animal care and use procedures were conducted in
a c c o r d a n c ew i t ht h eG u i d ef o rt h eC a r ea n dU s eo f
Laboratory Animals (National Research Council) and
approved by the Institutional Animal Care and Use
Committee. Experiments conducted in vivo were per-
formed on 8-12-week-old male C57BL/6J mice obtained
from a colony raised in our laboratory. Mice were indi-
vidually housed in standard shoebox cages, with wood
shavings as litter, in a temperature- (23°C) and humid-
ity- (45-55%) controlled environment with a 12/12 h
modified dark-light cycle (lights on 10:00 P.M.-10:00 A.
M.). Food and water were available ad libitum.
Intracerebroventricular (i.c.v.) Cannulation
A stainless steel guide cannula (23-gauge, 7 mm length)
was surgically implanted unilaterally 0.5 mm above the
lateral ventricle of the brain, as previously described
[38]. After anesthetizing with ketamine and xylazine
(1 mg and 0.1 mg/10 g body weight i.p., respectively),
mice were secured in a Kopf stereotaxic instrument
(Tujunga, CA, USA). Coordinates for placement of the
guide cannula were 1 mm posterior to bregma, 1.6 mm
lateral and 2.0 mm below the skull surface at the point
of entry. Mice were allowed to recover a minimum of
7 days before treatment and initiation of behavioral
tests. After recovery, mice were slowly injected over
1m i ni.c.v. with sterile saline or LPS (100 ng) in a
volume of 1 μl. This dose of LPS was selected on its
ability to reliably induce sickness behavior [37-39]. The
cannula was left in place for 1 min following injection.
Behavioral Experiments
All behavioral experiments were performed during the
first 4 h of the dark phase of the light cycle and were
video taped.
Social exploration behavior
Social exploration was carried out before and then 4, 8,
and 24 h post i.c.v. injection using a protected novel
juvenile that was introduced into the test subject’s home
cage for a five-min period. Social behavior was deter-
mined as the amount of time that the experimental sub-
ject spent investigating the juvenile [38].
Forced swim test
The forced swim test was conducted at 24 h post i.c.v.
injection for a six-min period. Immobility was defined
as passive floating behavior or any movement necessary
for the mouse to keep its head above water, as described
previously [30].
Organotypic Hippocampal Slice Cultures
Hippocampal slice cultures were prepared using the sta-
tic interface culture method [39]. Briefly, 6- to 8-day-old
C57BL/6J mice were euthanized by decapitation. The
brains and meninges were removed, followed by separa-
tion of the hippocampus from both hemispheres. Hippo-
campi were dissected and transverse slices (350 μmi n
thickness) were prepared with a McIlwain tissue chop-
per (Campden Instruments Ltd, UK). Slices were placed
for 1 h at 4°C into GBSS supplemented with 2 mg/ml
D-glucose and were then transferred onto porous (0.4
μm) transparent membrane inserts (30 mm in diameter;
Millipore) with five slices on each insert. Inserts were
then placed into six-well culture plates. Each well con-
tained 1.2 ml of nutrient medium composed of 25%
heat-inactivated horse serum, 25% HBSS and 50%
MEM, supplemented with 25 mMD -glucose. Neither
antibiotics nor anti-mitotics were used. Plates were
maintained in a humidified CO2 incubator (5% CO2,
95% atmospheric air) at 37°C. Medium was changed
every 2-3 days. The MEM medium was changed so that
it contained only 5% horse serum and 25 mM D-glucose
on the day that LPS was added. At various times follow-
ing addition of LPS, supernatants were collected and
stored at -80°C for measurement of cytokines. Slices
were washed twice with cold PBS and stored at -80°C
for isolation of total cellular RNA and determination of
IDO enzymatic activity.
Slice staining
Brain slices were stained at several times after sectioning
by adding PI to label dead cells. Slices were incubated at
37°C for 30 min in 2 μM PI. Slices were then imaged
using an Axiovert 40 CFL microscope equipped with
Axio CamMR using a 2.5× objective. Measurement of
the intensity of PI staining was quantified using
AxioVision.
Reverse transcription and Real-time RT-PCR
Total cellular RNA from the hippocampus and cultured
slices was extracted in TRIzol reagent, as previously
described [16]. Total mRNA (1-2 μg) was reverse tran-
scribed to cDNA using reverse transcriptase kits from
Ambion. Samples were run in duplicate. Data were ana-
lyzed using the comparative threshold cycle method, as
described elsewhere (Applied Biosystems User Bulletin
no.2).
Enzyme-linked immunosorbent assays (ELISAs)
TNFa and IL-6 were measured with validated specific
ELISA assays according to the manufacturer’s
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duplicate to ELISA plates pre-coated with an anti-TNFa
or IL-6 capture antibody. Recombinant murine TNFa
and IL-6 standards ranged from 0 to 1,000 pg/ml. The
lower assay limit of detection was 16 pg/ml. Absorbance
was measured on an OPTImax ELISA plate reader.
TNFa and IL-6 concentrations were expressed as pico-
grams per milliliter.
Determination of IDO activity
IDO activity was measured as previously described [40],
with minor modifications. Briefly, slices were disrupted
with ice-cold lysing buffer (140 mM KCl, 20 mM potas-
sium phosphate buffer, pH 7.0) with a cocktail of pro-
tease inhibitors. After centrifugation of the homogenates
(13,000 × g, 10 min, 4°C), supernatants were incubated
for 1 h at 37°C in the following reaction mixture: 0.4
mM L-TRP, 20 mM ascorbate, 10 μMm e t h y l e n eb l u e ,
100 μg catalase in 50 mM phosphate buffer, pH 6.5.
The reaction was stopped by addition of 10% sulfosa-
licylic acid solution (SSA), followed by incubation for 30
min at 50°C to convert N-formylkynurenine to L-kynur-
enine (L-KYN). After centrifugation (13,000 × g, 10 min,
4°C) and ultrafiltration (0.2 μM filter tubes), the amount
of L-KYN produced from TRP was determined by High
Pressure Liquid Chromatography (HPLC) with electro-
chemical detection, as previously described [14]. Enzy-
matic activity was expressed as the product content per
hour per milligram of protein.
Statistical analysis
Data from social exploration were analyzed using a two-
way (treatment × time) ANOVA with repeated measures
on the time factor. Data from other experiments were
analyzed using a one-way (treatment) ANOVA, followed
by a Fisher’sL S Dpost hoc test if the main effect was
significant. All data are presented as means ± SEM. Dif-
ferences were considered significant if the probability
reached a level of 0.05 or smaller.
Results
Central LPS challenge induces an episode of sickness
behavior followed by depressive-like behavior
Peripheral LPS injection causes depressive-like behavior
at 24 h in the absence of sickness response [14,21], so
we sought to determine if similar behavioral changes
could be induced by centrally administered LPS at a
dose (100 ng) that we previously established to induce
sickness behavior in both CD1 [41] and C57BL/6J
[42,43] mice. LPS-induced sickness was measured by
assessing body weight and social exploration. As
expected, i.c.v. administration of LPS induced a signifi-
cant reduction in body weight 6 h after LPS injection
compared to saline-treated c o n t r o l s( - 0 . 4±0 . 3( n=4 )
vs. 0.5 ± 0.1 g (n = 5); p <0 . 0 5 ) .L P Sr e d u c e ds o c i a l
exploration in a time-dependent manner (treatment ×
time: p < 0.01). Social exploration was reduced at 4 h (p
< 0.01) and 8 h (p < 0.05), returning to baseline explora-
tion by 24 h after i.c.v. injection of LPS (Fig. 1A). In
Figure 1 LPS administered via the i.c.v. route induces both sickness and depressive-like behavior.M i c ew e r ei n j e c t e di.c.v.w i t he i t h e r
saline or LPS (100 ng). (A) Social behavior was measured during a 5 min period at 0, 4, 8 and 24 h following LPS injection. (B) Duration of
immobility was quantified during a 6 min forced swim test that was recorded 24 h following administration of LPS. Data represent mean ± SEM
(n = 4-6 mice/group). * p < 0.05, ** p < 0.01 compared to saline.
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post-treatment (Fig. 1B, p < 0.01). Collectively, these
data establish that acute activation of the central innate
immune system with LPS in mice induces depressive-
like behavior that does not overlap with sickness
behavior.
Central LPS challenge induces IDO, cytokine and iNOS
expression in the hippocampus
We have established that IDO and cytokine expression
in the hippocampus of mice injected i.p. with LPS peaks
within 6 h [29]. Therefore, the hippocampus was col-
lected at the 6 h time point to determine the effects of
LPS injected i.c.v.o nt h eb r a i n .A l t h o u g hI D Om R N A
was undetectable in saline-treated mice, its expression
increased significantly following central injection of LPS
(p < 0.05) (Fig. 2A). LPS also increased TNFa (p <0 . 0 1 ;
Fig. 2B), IL-6 (p < 0.01; Fig. 2C), and iNOS (p <0 . 0 5 ;
Fig. 2D) mRNA expression compared to saline-injected
controls. LPS did not cause a statistically significant
increase in IFNg mRNA expression (data not shown).
These results indicate that centrally administered LPS
activates brain cytokine signaling and increases brain
IDO expression.
Hippocampal slices largely recover from explantation by
day 7 in tissue culture
In order to investigate the mechanisms responsible for
inflammation-induced depression, organotypic cultures
of hippocampal slices were prepared from 6 to 8-day-
old C57BL/6J mice. Preparation of murine hippocam-
pal slices from postnatal brain requires cutting the hip-
pocampus. We reasoned that the trauma caused by
removal of afferents and efferents induced by the
transversal slicing of hippocampus would cause an
acute, but not chronic, inflammatory reaction. In order
to assess the length of time required by OHSCs to
recover, we collected both tissue slices and media at
various time points to measure mRNA expression and
protein levels of proinflammatory cytokines using real-
Figure 2 Central administration of LPS induces (A) IDO, (B) TNFa, (C) IL-6 and (D) iNOS mRNA upregulation in the hippocampus. Mice
were injected i.c.v. with either saline or LPS (100 ng) and the hippocampi were collected 6 h later. Steady-state expression of mRNA transcripts
was measured by real-time RT-PCR. Average Ct values for LPS-treated mice were as follows: IDO = 33.0 ± 0.4; TNFa = 23.3 ± 0.4; IL-6 = 24.2 ±
0.4; iNOS = 28.0 ± 0.3. Data represent mean ± SEM (n = 4-5 mice/group). * p < 0.05, ** p < 0.01 compared to saline.
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6 h treatment) was used as a positive control to treat
OHSCs on day 10.
Immediately after transversal slicing on day 0, mRNA
from hippocampi was isolated. Although mRNA for
TNFa, IL-6 and iNOS could be detected immediately
after slicing on day 0, the amount was extremely low,
particularly compared to the amount induced by LPS
later in culture (Fig. 3). Indeed, after 10 days in culture,
treatment with LPS dramatically increased expression of
TNFa, IL-6 and iNOS mRNA and induced roughly a
nanogram per milliliter secretion of TNFa and IL-6 pro-
tein in the culture medium (Fig. 3). The amount of
mRNA and protein caused by transversal slicing was
minimal compared to treatment with LPS, but nonethe-
less, was detectable in several instances. For example,
TNFa mRNA increased on both days 1 and 3 (p <0 . 0 1 )
after slicing, but it returned to low but detectable levels
by day 7. However, the increase in amplified mRNA for
TNFa was not accompanied by any detectable TNFa
released into the medium at any time point. There was
a temporary increase in IL-6 mRNA on day 1 (Fig. 3,
p < 0.01). IL-6 protein in the culture medium was sig-
nificantly increased on days 1 and 3 (p < 0.01). Expres-
sion of iNOS mRNA was only slightly increased (3-fold;
p < 0.01) on day 1. This modest increase in iNOS
mRNA was not associated with any increase in nitrite
levels in the culture medium, as measured by Griess
reaction (data not shown).
The viability of OHSCs was determined by PI staining
[44]. As shown in Fig. 4, dead/dying cells could be
detected in the dentate gyrus (DG), CA1 and CA3
regions (p < 0.01) during the first 3 days of OHSCs cul-
ture. This was followed by a gradual decline in the pro-
portion of PI-positive cells. Quantitative analysis
confirmed that PI uptake significantly increased on day
Figure 3 Proinflammatory cytokines and iNOS expression in hippocampal slices at the mRNA and protein level.D a y0r e p r e s e n t s
freshly-isolated hippocampi that were subjected to transversal slicing and mRNA being prepared immediately following slicing. Culture media
and slice tissue were collected on days 1, 3, 7, 10 and 14 after the start of the culture. LPS (10 ng/ml) was used as a positive control on day 10,
with mRNA and protein being measured 6 h later. Steady-state expression of mRNA transcripts was measured by real-time RT-PCR, and
proinflammatory cytokines in the media were measured by ELISA. Average Ct values for at 1, 3, 7, 10 and 14 days for each mRNA species were,
respectively: TNFa: 27.6 ± 0.7, 27.8 ± 0.5, 29.0 ± 0.3, 29.1 ± 0.5, 28.7 ± 0.6; IL-6: 30.7 ± 0.4, 34.8 ± 0.2, 36.1 ± 0.9, 35.8 ± 0.8, 36.6 ± 1.1; iNOS: 28.8
± 0.8, 31.8 ± 0.8, 31.1 ± 1.0, 32.9 ± 0.3, 35.5 ± 0.8. Data represent the mean ± SEM (n = 3 in each group). Bars labeled with different letters (a, b,
c or d) are significantly different from each other at p < 0.05.
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days 7 through 14. The OHSCs responded very well to
LPS at day 10 (Fig. 3), so the decline in proinflammatory
cytokine expression that occurred with increasing time
i nc u l t u r ew a sv e r yu n l i k e l yt oh a v eb e e nc a u s e db yc e l l
death. Collectively, results of these experiments confirm
that transversal slicing of the hippocampus causes an
acute inflammatory response. These data also establish
that OHSCs almost entirely recover from the explanta-
tion procedure within 7 days.
Organotypic hippocampal slice cultures respond to LPS
by increased expression of proinflammatory cytokines
Based on the in vivo response to central injection of LPS
(Fig. 2), the time point of 6 h was selected for carrying
out dose-response experiments to determine the effect
of LPS on cytokine expression. Slices were exposed to 1,
10 and 100 ng/ml of LPS on day 10 in culture. As
shown in Fig. 5A, LPS increased TNFa and IL-6 produc-
tion at both the mRNA (p < 0.05) and protein (p < 0.01)
levels in a dose-dependent manner, with a maximum at
10 ng/ml. In control cultures containing medium alone,
neither TNFa nor IL-6 could be detected. iNOS mRNA
r e a c h e dam a x i m u ma t1 0 0n g / m lL P S( p <0 . 0 1 )b u t
this was not associated with a detectable increase in
nitrite levels at the 6 h time point (data not shown).
Nitrite levels remain undetectable in control OHSCs
through at least 13 days in culture. Following LPS sti-
mulation, nitrites begin to rise to detectable levels only
after 48 h, which allows adequate amounts to accumu-
late in the medium (data not shown).
For kinetic studies, OHSCs were exposed to 10 ng/ml
LPS for 6, 12, 18 and 24 h on day 10 of culture. As
shown in Fig. 5B, the greatest expression of both mRNA
and protein for TNFa occurred at 6 h (p < 0.01). In con-
trast, IL-6 mRNA peaked at 6 h (p < 0.01) and gradually
returned to the control level at 24 h. IL-6 concentration
in the culture medium increased after 6 h (p < 0.01)
and reached a maximum at 24 h (p <0 . 0 1 ) .i N O S
mRNA increased at 6 h (p < 0.01) and peaked at 12 h
(p < 0.01), but there was no concomitant increase in
nitrite levels at any time point. These results reflect the
capability of OHSCs to respond to inflammatory stimuli
in a manner similar to that which occurs in vivo,i n d i -
cating that OHSCs represent a reliable and valuable
model for investigating neuroimmune interactions in a
mouse system.
LPS induces expression of IDO in the absence of IFNg
transcripts in murine OHSCs
We recently established that LPS induces expression of
IDO in primary murine microglial cells in the absence
Figure 4 Time course of cell death in OHSCs. The OHSCs were treated with PI at different time points after the start of culture. Red
fluorescence indicates the dead-cell population using PI staining. Bars represent the mean ± SEM (n = 3 in each group). Bars labeled with
different letters (a, b or c) are significantly different from each other at p < 0.05. Scale bar = 500 μm.
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PCR to determine whether LPS induces IDO steady-
state transcripts in OHSCs as it does in vivo at 6 h. To
determine an optimal dose for LPS-induced expression
of IDO, OHSCs were treated with 1, 10 and 100 ng/ml
of LPS for 6 h. As shown in Fig. 6A, IDO mRNA
expression could be detected at 1 ng/ml LPS and
reached a maximum at 10 ng/ml LPS (p < 0.05). Kinetic
studies were then carried out in which OHSCs were
exposed to LPS (10 ng/ml) for 6, 12, 18 and 24 h. Figure
6B shows that IDO mRNA could not be detected in
OHSCs prior to addition of LPS (40 amplification
cycles). However, IDO expression was strongly but tran-
siently induced by LPS at 6 h (p < 0.01), returning to
the same level as time 0 by 12 h. Importantly, this LPS-
induced expression of IDO did not require endogenous
synthesis of IFNg because no IFNg mRNA could be
detected at any time point in LPS-stimulated slices (40
amplification cycles, data not shown). Similarly, we
found that LPS did not cause a statistically significant
increase in IFNg mRNA expression at the earlier time
point of 2 h (data not shown). This finding using
OHSCs is consistent with the results of recent studies
reporting that IFNg-independent mechanisms can med-
iate IDO induction in hippocampal neurons [45] and
primary murine microglial cells [37].
LPS increases IDO enzymatic activity in OHSCs
To assess whether OHSCs express functional IDO, we
determined IDO enzymatic activity by measuring the
amount of kynurenine formed following incubation of
OHSCs lysates with exogenous L-tryptophan (Fig. 6C).
These experiments showed that IDO enzymatic activity
increased with time following exposure to LPS. IDO
enzymatic activity was augmented by LPS at 8 h (p <
0.01), and this functional activity remained elevated at
12 and 18 h (p < 0.01) of culture compared to medium
control. By 24 h, IDO enzymatic activity returned to
baseline. These findings are consistent with our previous
data showing that LPS-induced increases in brain IDO
mRNA precede activation of IDO and are associated
with increased IDO enzymatic activity in vivo [14] and
in primary murine microglia [37].
Discussion
Experiments in this report were designed to answer
three major questions: (1) Can a direct central challenge
with LPS activate IDO in the hippocampus and induce
depressive-like behavior? (2) Can a murine organotypic
culture system serve as a reliable in situ model for
investigating mechanistic aspects of the depressive
effects of inflammation? (3) Does this in situ model of
OHSCs respond like primary microglia in vitro where
IDO induction can occur via an IFNg-independent
mechanism? To our knowledge, this is the first report to
demonstrate that centrally administered LPS induces
depressive-like behavior as measured by increased
immobility in the forced swimt e s ta f t e rs i c k n e s sb e h a -
vior has dissipated and this effect is associated with IDO
activation. Furthermore, the effect of LPS on IDO pro-
duction in vivo translates to the in situ setting, and IDO
activation in response to LPS occurs in the absence of
up-regulation of transcripts for IFNg. Thus, murine
OHSCs can be reliably used to study the mechanisms of
Figure 5 LPS induces proinflammatory cytokines and iNOS expression in OHSCs in a dose- and time-dependent manner. (A) 1, 10 or
100 ng/ml LPS were added to the medium after 10 days in culture. Tissue and media were collected 6 h later. Average Ct values for 1, 10 or
100 ng/ml LPS were, respectively, for TNFa: 20.6 ± 0.6, 19.6 ± 0.5, 19.6 ± 0.6; IL-6: 24.1 ± 0.6, 22.5 ± 0.6, 22.1 ± 0.6; iNOS: 26.2 ± 0.9, 24.9 ± 1.0,
23.6 ± 0.9. (B) Hippocampal slices were treated with LPS (10 ng/ml) and tissue and media were collected at various times. Average Ct values at
6, 12, 18 and 24 h were, respectively, for TNFa: 19.7 ± 0.1, 22.8 ± 0.7, 24.4 ± 0.9, 25.3 ± 0.7; IL-6: 23.2 ± 0.3, 24.9 ± 0.7, 28.1 ± 1.1, 28.8 ± 0.7; iNOS:
24.1 ± 0.1, 22.7 ± 0.6, 24.4 ± 1.1, 25.2 ± 1.0. Amount of the proinflammatory cytokines was measured by ELISA. Bars represent the mean ± SEM
(n = 3 in each group). Bars labeled with different letters (a, b, c, d or e) are significantly different from each other at p < 0.05.
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of cytokine synthesis due to preparation of the slices.
Activation of brain cytokine signaling in response to
peripheral or central administration of LPS has repeat-
edly been demonstrated to mediate LPS-induced sick-
ness behavior [2,6,46]. In the present study, i.c.v.L P S
induced sickness behavior, as measured by body weight
loss and decreased social exploration, and this effect was
associated with increased expression of steady-state
transcripts for TNFa, IL-6, iNOS and IDO in the hippo-
campus. Moreover, i.c.v. administration of LPS was suffi-
cient to induce depressive-like behavior, as measured by
increased immobility in the forced swim test when
social exploration had dissipated. These results are an
important conceptual advance since the association
between LPS-induced depressive-like behavior and acti-
vation of hippocampal IDO indicates that kynurenine
does not need to enter the brain from the periphery to
induce depressive-like behavior.
The choice of the hippocampus as a target structure
for ex vivo analysis of cytokine expression in response to
LPS was not motivated by consideration of the possible
role of this brain area in major depressive disorders
[27,47,48] but by the need to compare ex vivo data to in
situ data collected in OHSCs. Compared to primary cul-
tures of brain cells, OHSCs have the advantage of con-
serving some form of neuroanatomical organization
together with functional cell-to-cell interactions [32,33].
OHSCs recreate an intact brain microenvironment that
preserves the cytoarchitecture and functional informa-
tion-processing properties of neurons. The morphologi-
cal characteristics of neurons and glial cells in
hippocampal slice cultures have been studied by both
light and electron microscopy. During slice preparation,
cutting of afferent and efferent axons inevitably leads to
a rearrangement of connectivity over the following days.
Most cells on the slice surface are healthy, receiving and
sending inputs from intact axons, and both increased
excitatory miniature synaptic current frequency and
dendritic complexity are established within the first
week of culture [49]. During the first 2 days of culture,
astrocytes appear thin and elongated in the rat system.
Figure 6 LPS increases IDO mRNA and enzymatic activity in OHSCs. (A) 1, 10 or 100 ng/ml LPS were added to the medium after 10 days in
culture. Tissue and media were collected 6 h following addition of LPS. Average Ct values for 1, 10 or 100 ng/ml LPS for IDO were, respectively,
38.4 ± 0.8, 36.4 ± 0.3, 36.4 ± 0.3. (B) Hippocampal slices were treated with LPS (10 ng/ml) for various times. Average Ct values at 6, 12, 18 and
24 h for IDO were, respectively, 36.7 ± 0.4, 39.5 ± 0.5, 39.7 ± 0.4, 40 ± 0. (C) Hippocampal slices were treated with LPS (10 ng/ml) for 8, 12, 18
and 24 h. IDO enzymatic activity was determined by measuring the amount of kynurenine formed upon incubation of slices lysates with
exogenous L-tryptophan. IDO enzymatic activity was expressed as a percentage of the medium control. Bars labeled with different letters (a or
b) are significantly different from each other at p < 0.05.
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and form a gliotic scar over the surface of the culture.
“Reactive/activated” microglia reaches peak numbers
immediately after injury induced by culture preparation.
These ameboid microglia are replaced after 10 days in
culture by “resting/ramified” microglia [50]. Since long
term organotypic cultures of the murine hippocampi
have been rarely used in neuroimmunology, it was
necessary first to validate this model system. The early
but transient increases in TNFa and IL-6 expression and
release in response to the traumatic injury caused by
transversal sectioning probably originated from activated
microglial cells. After several days in vitro, the decline
in the production of cytokines to baseline almost cer-
tainly reflected the return of microglia to their non-acti-
vated phenotype. However, this conclusion still needs to
be confirmed using appropriate techniques.
Most dead cells disappeared and cytokines could no
longer be detected in the culture medium after the first
week of culture. This finding indicates that the inflam-
matory profile has certainly subsided, such that murine
OHSCs can be safely used as soon as after 7 days in cul-
ture. In the rat system, the optimal time window for
experiments is between day 6 and day 18 [51]. At this
time, most of the slices are healthy and vital. After this
time, the percentage of usable slices decreases, but
v i a b l er a tO H S C sc a nl a s tam i n i m u mo f6 - 8w e e k si n
culture [51]. In the present conditions of murine
OHSCs, LPS evoked a substantial expression of mRNA
as well as the synthesis and release of TNFa and IL-6.
T h e s ed a t ac o n f i r mr e s u l t sp reviously reported in rat
OHSCs [52]. It is important to note that the concentra-
tion of LPS-induced TNFa and IL-6 production were
significantly higher than the levels measured at the
onset of the organotypic culture.
Glial cells are the main sources of cytokines in CNS
injury and inflammation [53]. TNFa produced at the
earlier time point of 6 h probably originates from acti-
vated microglia whereas the peak in IL-6 that occurred
at 24 h is produced by astrocytes that are subsequently
activated by TNFa [53]. We did not report changes in
IL-1b mRNA or protein in OHSCs since the release of
IL-1b in the culture medium requires the addition of
ATP (data not shown). This implies that the production
of IL-6 was likely solely dependent on TNFa production.
We were most interested in the potential use of mur-
ine OHSCs to determine whether LPS can activate IDO
in this in situ system. We previously demonstrated that
IDO, the first and rate-limiting enzyme in the synthesis
of kynurenine from the precursor of tryptophan, is a
required mediator of depressive-like behavior in
response to LPS in mice [14]. The increase in brain
IDO activity is invariably preceded by enhanced expres-
sion of IDO mRNA, which can therefore be used as a
surrogate marker of IDO activation [14,37]. Expression
and activation of IDO in response to LPS and other sti-
muli are usually studied in various types of transformed
and primary cell cultures. However, murine OHSCs cul-
tures have never been used for this purpose despite
their potential advantages for the study of the intricate
cell-to-cell communication mechanisms that mediate
activation of IDO in the brain. In situ hybridization stu-
dies of the expression of IDO in the brain in response
to LPS indicate that endothelial cells are the likely
source of brain IDO [14] whereas immunohistochemis-
try findings point to a possible neuronal localization
[54]. IDO is expressed in all types of brain cells that
have been studied so far, including endothelial cells, glia
and neurons [18]. The fate of IDO-produced kynurenine
is not the same in microglia and other cell types because
of differences in the intracellular enzymes that metabo-
lize kynurenine [20]. Therefore, it is obviously important
to determine in future experiments which brain cell
types are predominantly involved in the production and
d e g r a d a t i o no fk y n u r e n i n ei nr e s p o n s et oa ni m m u n e
stimulus.
IFNg is considered to be the prototypical inducer of
IDO in a variety of cell types [55] as well as in clinical
situations in which inflammation-associated depression
occurs [11]. However, IFNg-independent activation
pathways have also been reported in response to LPS
[56,57]. LPS-induced upregulation of IDO in the brain
parallels increased IFNg mRNA expression in vivo [14]
but whether this leads to increased mature IFNg protein
can be disputed [58]. This does not mean that brain
macrophages and microgliaa r ec a p a b l eo fp r o d u c i n g
IFNg in other circumstances, even if most IFNg is nor-
mally produced by T lymphocytes and NK cells [59].
In conclusion, results of the present study clearly
demonstrate that direct, central activation of brain cyto-
kine signaling and IDO is associated with development
of depressive-like behavior in the mouse. These results
provide further arguments for the targeting of brain
IDO to alleviate inflammation-associated depression.
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